Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. About 3.2 billion people – almost half of the world’s population – are at risk of malaria. In 2015, there were 214 million cases of malaria causing 438,000 deaths. Selecta’s SVP prophylactic vaccine is designed to activate the immune system in order to enable a dual action vaccine by individually optimizing nanoparticles against multiple antigens and by allowing their combinatorial testing. If successful, a dual action, immune-activating SVP nanoparticle vaccine could offer the potential to protect against malaria by both fighting the parasite during early infection, and simultaneously blocking malaria transmission via infected mosquitoes.
This malaria vaccine program has been primarily financed through grants from the Bill and Melinda Gates Foundation and The National Institutes of Health (NIH).